The Bill & Melinda Gates Foundation has committed USD 17 million to support the development of CS-2036, a recombinant polio vaccine, by China-based CanSino Biologics (SHA: 688185, HKG: 6185). The investment will fund various development efforts, including clinical trials, process development, scaling-up, and the development of a candidate combined vaccine for CS-2036.
The CS-2036 candidate vaccine is a non-infectious virus-like particle (VLP) poliomyelitis vaccine developed using CanSino’s protein structure design and VLP assembly technology. It does not require live viruses during production, offering expected benefits in terms of safety and immunogenicity. The non-communicable VLP poliomyelitis vaccine has been endorsed by the World Health Organization as a preferred vaccine for future polio eradication efforts, setting it apart from existing attenuated and inactivated polio vaccines.
On the same day, CS-2036 initiated a Phase I/II clinical study in Indonesia, marking a significant step in the vaccine’s development and potential global health impact. – Flcube.com
